Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Submits Application For Fixed-Dose Blopress And Diuretic Combination In Japan

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical submitted a new drug application for a fixed-dose combination tablet of Blopress (candesartan cilexetil) and diuretic (hydrochlorothiazide) for treatment of hypertension to Japan's Ministry of Health, Labor and Welfare. Launched in 1999, Blopress is an angiotensin II receptor blocker and has become the first ARB indicated for chronic heart failure in Japan. Hydrochlorothiazide is classified as a thiazide diuretic and lowers blood pressure by increasing the flow of urine. Takeda's Development Division General Manager Masaomi Miyamoto said the application will maximize the value of Blopress. Currently, Takeda has fixed-dose combinations of Actos with sulfonylurea, and Actos with biganide, which are being marketed overseas. (Click here for more - Japanese language

You may also be interested in...



EU Decision Thwarts Novartis's Near-Term Piqray Ambitions

Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.

UK COVID Second Wave Could Drive OTC Paracetamol And Ibuprofen Prices Back Up

Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again. 

EU Business Round-Up: Sanofi Pens Enzymatica Deal, Germany's WindStar Acquired, Ipsen's Sales Slump

Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel